» Articles » PMID: 38961350

Association Between Asthma and COVID-19 Severity During Omicron Epidemic: a Retrospective Cohort Study Using Real-world Data

Abstract

Background: The available evidence presented inconsistencies and inconclusive findings regarding the associations between co-existing asthma and mortality among COVID-19 patients. The objective of the current study is to investigate the relationship between asthma and severe outcomes after SARS-CoV-2 Omicron infection in an infection-naïve population.

Methods: A retrospective cohort study using propensity score matching was conducted. The COVID-19 patients requiring hospitalisation in Hong Kong from January 1, 2022, to November 13, 2022, an Omicron-predominated period, were identified. Severe clinical outcomes were defined as ICU admission and inpatient death after the first positive PCR results as well as a composite outcome of both.

Results: Of the 74,396 hospitalised COVID-19 patients admitted, 1,290 asthma patients and 18,641 non-asthma patients were included in the matched cohort. The rates of death and the composite outcome were 15·3% and 17·2%, respectively, among the non-asthma patients,12·2% and 13·6%, respectively, among the asthma patients, with adjusted hazard ratios equal to 0·775 (95% CI: 0·660-0·909) and 0·770 (95% CI: 0·662-0·895), respectively. The negative association was more apparent in the elderly and female groups. Asthma remained a factor that lowered the risk of disease severity even though the patients were not fully vaccinated with at least two doses.

Conclusions: We used real-world data to demonstrate that asthma was not a risk factor for COVID-19 severity of the infections of Omicron variant, even though the patients were not fully vaccinated.

Citing Articles

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study.

Lin G, Wei Y, Guo Z, Wang H, Chan K, Chan R Respir Res. 2025; 26(1):75.

PMID: 40022135 PMC: 11871785. DOI: 10.1186/s12931-025-03156-2.

References
1.
Schultze A, Walker A, Mackenna B, Morton C, Bhaskaran K, Brown J . Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020; 8(11):1106-1120. PMC: 7515601. DOI: 10.1016/S2213-2600(20)30415-X. View

2.
Yang J, Koh H, Moon S, Yoo I, Ha E, You S . Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol. 2020; 146(4):790-798. PMC: 7428784. DOI: 10.1016/j.jaci.2020.08.008. View

3.
Busse W, Lemanske Jr R, Gern J . Role of viral respiratory infections in asthma and asthma exacerbations. Lancet. 2010; 376(9743):826-34. PMC: 2972660. DOI: 10.1016/S0140-6736(10)61380-3. View

4.
Wong C, Au I, Lau K, Lau E, Cowling B, Leung G . Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022; 22(12):1681-1693. PMC: 9401976. DOI: 10.1016/S1473-3099(22)00507-2. View

5.
Choi Y, Park J, Lee H, Suh J, Song J, Byun M . Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2020; 57(3). PMC: 7518077. DOI: 10.1183/13993003.02226-2020. View